People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

The body's immune system mistakenly produces "autoantibodies," or antibodies that attack its own tissues and proteins. In the case of myasthenia gravis, the body produces autoantibodies that ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

In the autoimmune disease myasthenia gravis, self-directed autoantibodies bind to the AChR, causing muscle weakness through several ways. Must be used in conjunction with Cell study on myasthenia ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised ...

Myasthenia gravis is a rare neuromuscular disorder caused by the production of pathogenic autoantibodies against neuromuscular junction components. About 80-85% of gMG patients have antibodies ...

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...